| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Necchi, Andrea Pond, Gregory R. Giannatempo, Patrizia Di Lorenzo, Giuseppe Eigl, Bernhard J. Locke, Jenn Pal, Sumanta K. Agarwal, Neeraj Poole, Austin Vaishampayan, Ulka N. Niegisch, Guenter Hussain, Syed A. Singh, Parminder Bellmunt, Joaquim Sonpavde, Guru |
| Description |
Country affiliation: Italy Author Affiliation: Necchi A ( Department of Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.); Pond GR ( Department of Statistics, McMaster University, Hamilton, Ontario, Canada.); Giannatempo P ( Department of Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.); Di Lorenzo G ( Department of Medicine, University Federico II, Naples, Italy.); Eigl BJ ( Department of Medicine, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.); Locke J ( Department of Medicine, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.); Pal SK ( Department of Medicine, City of Hope Cancer Center, Duarte, CA.); Agarwal N ( Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT.); Poole A ( Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT.); Vaishampayan UN ( Department of Medicine, Wayne State University Cancer Center, Detroit, MI.); Niegisch G ( Department of Urology, Heinrich Heine University, Dusseldorf, Germany.); Hussain SA ( Department of Medicine, University of Liverpool, Liverpool, United Kingdom.); Singh P ( Department of Medicine, University of Arizona, Tucson, AZ.); Bellmunt J ( Department of Medicine, Dana Farber Cancer Institute, Boston, MA.); Sonpavde G ( Department of Medicine, UAB Comprehensive Cancer Center, Birmingham, AL. Electronic address: gsonpavde@uabmc.edu.) |
| Abstract |
BACKGROUND: Outcomes with cisplatin-based first-line therapy for advanced UC after previous perioperative cisplatin-based chemotherapy are unclear. In this study we evaluated outcomes with a focus on the effect of time from previous cisplatin-based perioperative chemotherapy. PATIENTS AND METHODS: Data were collected for patients who received cisplatin-based first-line therapy for advanced UC after previous perioperative cisplatin-based therapy. Cox proportional hazards models were used to investigate the prognostic ability of visceral metastasis, ECOG PS, TFPC, anemia, leukocytosis, and albumin on overall survival (OS). RESULTS: Data were available for 41 patients from 8 institutions including 31 men (75.6%). The median age was 61 (range, 41-77) years, most received gemcitabine plus cisplatin (n = 26; 63.4%), and the median number of cycles was 4 (range, 1-8). The median OS was 68 weeks (95% confidence interval [CI], 48.0-81.0). Multivariable Cox regression analysis results showed an independent prognostic effect on OS for PS > 0 versus 0 (hazard ratio [HR], 4.56 [95% CI, 1.66-12.52]; P = .003) and TFPC ≥ 78 weeks versus < 78 weeks (HR, 0.48 [95% CI, 0.21-1.07]; P = .072). The prognostic model for OS was internally validated with c-index = 0.68. Patients with TFPC < 52 weeks, 52 to 104 weeks, and ≥ 104 weeks had median survival of 42, 70, and 162 weeks, respectively. CONCLUSION: Longer TFPC ≥ 78 weeks and ECOG PS = 0 were independently prognostic for better survival with cisplatin-based first-line chemotherapy for advanced UC after previous perioperative cisplatin-based chemotherapy. The data support using TFPC ≥ 52 weeks to rechallenge with cisplatin-based first-line chemotherapy for metastatic disease. |
| File Format |
HTM / HTML |
| ISSN |
15587673 |
| e-ISSN |
19380682 |
| DOI |
10.1016/j.clgc.2014.08.010 |
| Journal |
Clinical Genitourinary Cancer |
| Issue Number |
2 |
| Volume Number |
13 |
| Language |
English |
| Publisher |
Elsevier |
| Publisher Date |
2015-04-01 |
| Publisher Place |
United States |
| Access Restriction |
Open |
| Subject Keyword |
Discipline Urology Discipline Oncology Antineoplastic Agents Therapeutic Use Cisplatin Deoxycytidine Analogs & Derivatives Urinary Bladder Neoplasms Drug Therapy Urothelium Pathology Neoplasm Metastasis Perioperative Care Proportional Hazards Models Survival Analysis Mortality Surgery Drug Effects Multicenter Study |
| Content Type |
Text |
| Resource Type |
Article |
| Subject |
Urology Oncology |
